Nevertheless, in line with the Cdk12/13 depletion data (Supplemental Figure 7B), YJ1206 treatment exhibited substantially stronger control of tumor growth in immunocompetent mice compared with immunodeficient mice (Supplemental Figure 8A). This evidence concerns the gene CDK12 and neoplasm.